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Introduction
Chronic obstructive pulmonary disease (COPD) encompasses 
several clinical syndromes, most notably emphysema and chronic 
bronchitis. It represents a major unmet medical need and is strongly 
associated with cigarette smoke (CS) exposure. We previously 
demonstrated that CS and viruses utilize the RIG-I–like helicase 
(RLH) innate immune pathway to generate COPD-like alveolar 
destruction and airway remodeling and that the mitochondrial anti-
viral signaling molecule (MAVS) plays a key role in these responses 
(1). Here, we hypothesized that the tissue effects of CS are mediated 
by its ability to abrogate the effects of specific MAVS inhibitors and 
that the nucleotide-binding domain and leucine-rich repeat–con-
taining protein X1 (NLRX1) is a critical target of this CS-induced 
disinhibition. To test this hypothesis, we evaluated the expression 
of NLRX1 in 3 cohorts of patients with COPD and characterized the 
relations between NLRX1 suppression and disease severity. In addi-
tion, we evaluated the effects of CS on the expression of NLRX1 and 
defined the roles of MAVS and NLRX1 in CS-induced murine pul-
monary inflammation and alveolar remodeling responses.
Results and Discussion
We extracted the mRNAs from fresh-frozen lung tissues from the 
7 controls and 36 patients with COPD in the NIH-sponsored Lung 
Tissue Research Consortium (LTRC) cohort. The latter contained 
6, 10, 10, and 10 specimens from Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage 1, 2, 3, and 4 individuals, 
respectively (Supplemental Table 1A; supplemental material avail-
able online with this article; doi:10.1172/JCI71747DS1). Real-time 
RT-PCR analysis demonstrated that the levels of mRNA encoding 
NLRX1 were significantly decreased in patients with advanced 
stages of COPD (Figure 1, A and B). Western blot evaluations demon-
strated that NLRX1 protein expression was significantly decreased 
in patients with advanced stages of COPD (Supplemental Figure 1). 
NLRX1 expression correlated significantly with the patient’s forced 
expiratory volume in 1 second (FEV1; % predicted), an indicator of 
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These studies demonstrate that NLRX1 expression is selectively 
decreased in patients with COPD where this suppression correlates 
with clinical stage and parameters of disease severity.
We next evaluated the relationships between NLRX1 gene 
expression and clinical parameters of COPD. In the LTRC cohort, 
NLRX1 gene expression levels correlated with other measures 
of pulmonary function including diffusing capacity (DLCO) and 
6-minute walking distance (Supplemental Figure 6A and data not 
shown). The levels of NLRX1 mRNA correlated inversely with the 
BODE (BMI, airflow obstruction, dyspnea, and exercise) index 
and scores on the St. George’s Respiratory Questionnaire (SGRQ) 
(Supplemental Figure 6B and data not shown), which are predic-
tors of disease mortality and quality of life, respectively. NLRX1 
also correlated inversely with dyspnea as measured with the Borg 
scale at the termination of exercise (Supplemental Figure 6C). 
CXCL13, which is produced by lymphoid follicles in COPD (2) and 
inhibited via an NLRX1-dependent mechanism (see below), was 
significantly enhanced in patients with advanced stages of COPD, 
where it correlated inversely with the expression of NLRX1 and 
the patient’s FEV1 (%, predicted), DLCO, BODE index, and SGRQ 
scores (Supplemental Figures 7 and 8, and data not shown). These 
studies reinforce the relations between the suppression of NLRX1- 
regulated pathways and abnormal pulmonary function and high-
light the relations between NLRX1 suppression and mortality, 
poor quality of life, and exercise-induced dyspnea.
airflow limitation and a measure of COPD disease severity (Fig-
ure 1, C and D). Similar correlations were noted between NLRX1 
suppression and pre- and postbronchodilator FEV1, suggesting that 
these relationships are not related to reversible airway obstruction 
(Figure 1, C and D). In addition, similar suppression of NLRX1 was 
seen in a cohort of patients from the University of Pittsburgh (Sup-
plemental Table 1B) and was most impressive in those with severe 
emphysema (Figure 1E). Because the LTRC and Pittsburgh cohorts 
did not contain large numbers of patients with mild-to-moderate 
disease, we also studied a third cohort of Korean patients with 
mild-to-moderate disease (Asan cohort) (Supplemental Table 1C). 
Evaluation of this Asan cohort demonstrated that NLRX1 expres-
sion was also significantly decreased in patients with GOLD stage 
1 or 2 COPD, in whom it correlated significantly with the patient’s 
FEV1 (%, predicted) (Figure 1, F and G, Supplemental Figure 2, and 
Supplemental Figure 3, A and B). Almost all samples from the 3 
human cohorts were from former or current smokers (Supplemen-
tal Table 1), preventing the evaluation of smoking effects on NLRX1 
expression in these cohorts. There was no statistical difference in 
NLRX1 expression levels between former smokers and current 
smokers among the 3 human cohorts (Supplemental Figure 4 and 
data not shown). Finally, these alterations were at least partially 
NLRX1 specific, because the expression of related genes includ-
ing RIGI, MDA5, MAVS, NLRP3, and caspases 1, 4, and 5 were 
not similarly altered (Supplemental Figure 5 and data not shown). 
Figure 1. NLRX1 mRNA suppression in patients with COPD and its correlation with disease severity. (A) NLRX1 mRNA levels in LTRC samples were 
plotted for controls (0, no disease) and for patients with COPD of varying severity (GOLD 1, 2, 3, and 4). (B) NLRX1 mRNA levels were compared in subjects 
with no disease (controls, 0) and in patients with mild-to-moderate (GOLD 1 and 2) and severe COPD (GOLD 3 and 4). (C and D) Correlation between NLRX1 
mRNA levels in LTRC samples and prebronchodilator FEV1 (% of predicted value) and postbronchodilator FEV1 (% of predicted value). (E) Box-and-whisker 
plot for the Pittsburgh cohort depicting the relation between NLRX1 gene expression and radiologic emphysema (**P < 0.01 compared with control and the 
>40% emphysema group). (F and G) From the Asan cohort, NLRX1 gene transcriptome levels were plotted for controls versus patients with COPD and for 
controls versus patients with COPD of varying severity (GOLD 1, 2, and 3). Red bars in A, B, and G represent the mean ± SEM of the noted evaluations. Data 
were calculated using nonparametric Kruskal-Wallis (A), Mann-Whitney U (B), Pearson’s correlation (C and D), ANOVA (E and G), and 2-tailed t (F) tests. 
HU, Hounsfield units.
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To further define the mechanisms by which NLRX1 suppres-
sion mediates CS-induced pulmonary inflammation and alveolar 
remodeling responses, we evaluated the molecules and pathways 
that are believed to play important roles in COPD pathogenesis. 
In accord with the importance of protease-antiprotease balance, 
cell death, viral infection, and inflammasome activation in COPD 
pathogenesis (reviewed in refs. 4, 5), CS induction of Mmp12 
(Supplemental Figure 15A), cathepsins K and S (data not shown), 
type 1 Ifns (Supplemental Figure 15B), epithelial DNA injury and 
cell death (Supplemental Figure 15C), and caspase 1, IL-1β, and 
IL-18 activation (Figure 2, E and F, and Supplemental Figure 15D) 
was enhanced in Nlrx1-null mice compared with that observed in 
WT mice. Interestingly, CS exposure caused a modest increase 
in Cxcl13 in the lungs of WT mice, and this gene expression was 
synergistically upregulated in the lungs of NLRX1-deficient mice 
after 3 months of CS exposure (Supplemental Figure 16).
Finally, we performed studies to determine whether NLRX1 
supplementation could abrogate the phenotype in our CS-exposed 
mice in vivo. In these experiments, we used a lentiviral gene deliv-
ery system and exposed mice that had been given NLRX1 or con-
trols to CS for 6 months. These experiments demonstrated that 
CS-induced emphysematous alveolar destruction was markedly 
decreased in lungs of mice with NLRX1 overexpression com-
pared with that seen in control lungs (Figure 2G and Supplemen-
tal Figure 17). Taken together, these results suggest that NLRX1 
is a critical inhibitor of CS-induced pulmonary inflammation and 
tissue remodeling responses and that its inhibitory functions are 
decreased in pulmonary tissues by chronic CS exposure.
To define the role(s) of NLRX1 in CS-induced responses, we 
characterized the effects of CS on NLRX1 expression in WT mice 
and defined the CS-induced tissue responses in WT and Nlrx1-null 
(Nrlx1–/–) mutant animals. Indeed, the levels of pulmonary Nlrx1 
mRNA and NLRX1 protein were significantly decreased after 
CS exposure (Figure 2A and Supplemental Figure 9). Immuno-
histochemical staining of NLRX1 protein revealed that NLRX1 
expression was prominent in alveolar macrophages in both mice 
and humans (Supplemental Figures 10 and 11, respectively). West-
ern blot analysis of NLRX1 protein in BAL cells from lungs exposed 
to CS for 3 months, where more than 95% of total BAL cells are 
alveolar macrophages, further confirmed that NLRX1 protein was 
significantly suppressed after CS exposure (Figure 2B and Supple-
mental Figure 12A). The expression of MAVS protein, however, was 
not significantly altered in BAL cells after CS exposure (Figure 2B 
and Supplemental Figure 12B). This suppression of NLRX1 was at 
least partially reversible, because Nlrx1 gene expression returned 
to normal levels 3 months after the cessation of CS exposure (Sup-
plemental Figure 13). In keeping with reported experiments using 
WT mice, modest BAL and alveolar inflammation and modest 
alveolar destruction could be appreciated after 3 and 6 months 
of CS exposure, respectively (3). Importantly, these inflammatory 
and remodeling responses were markedly enhanced in lungs from 
CS-exposed Nlrx1–/– mice, which manifested enhanced BAL total 
cell, macrophage, and neutrophil recovery (Figure 2C and data not 
shown) and exaggerated emphysema that could be seen with his-
tologic and morphometric assessments after only 3 months of CS 
exposure (Figure 2D and Supplemental Figure 14).
Figure 2. CS-induced suppression of NLRX1 and the role of NLRX1 in CS-induced pulmonary inflammation and alveolar destruction. (A) Nlrx1 mRNA 
expression following CS exposure. After 3 months of CS exposure, (B) Western blot evaluation of NLRX1 in BAL cells, (C) BAL total cell recovery, (D) lung 
morphometry, (E) levels of active IL-18 in lung lysates measured by ELISA, and (F) activation status of IL-1β, IL-18, and caspase 1 in lung lysates. (G) Com-
parisons of the mean chord length in lungs from mice treated with lentiviral NLRX1 (NLRX1 vector+) and from controls (control vector+) after a 6-month 
exposure to CS. Data in A, C, D, E, and G represent the mean ± SEM of evaluations in a minimum of 5 mice (*P < 0.05; **P < 0.01). B and F are representa-
tive of a minimum of 3 similar experiments. The 2-tailed t test (A) and 2-way ANOVA (C–E and G) were used.
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a critical role in the exaggerated inflammatory, remodeling, 
proteolytic, cell death, and cytokine responses that are induced 
by CS in states of NLRX1 deficiency.
Studies of COPD and models of this disorder have highlighted 
the importance of antiviral innate immunity, protease excess, epi-
thelial cell death, and inflammasome activation in disease patho-
genesis (1, 3–5). Our studies add to and integrate these findings by 
demonstrating that mitochondria play an important role in the reg-
ulation and effector phases of CS-induced responses. Specifically, 
they demonstrate that NLRX1 is an important inhibitor of MAVS 
at baseline and that CS stimulates inflammation and remodeling 
by suppressing NLRX1. Inhibition of NLRX1 augmented antiviral 
innate immune responses, protease expression, cell death, and 
inflammasome activation, thereby mechanistically integrating the 
present and previous observations. The disease relevance of these 
studies was also confirmed in studies demonstrating that NLRX1 
expression is decreased in the lungs of patients with COPD, where 
this suppression correlates with disease severity, abnormal pulmo-
nary function, decreased quality of life, and poor prognosis.
NLRX1 is a member of the Nod-like receptor family of intra-
cellular sensors of microbial- and danger-associated molecular 
patterns (7, 8). In early studies, NLRX1 was identified to be a neg-
ative regulator of MAVS, a key adapter molecule of MAVS/RLH 
antiviral signaling (7). It is now known to be a negative modulator 
of LPS-induced TRAF6/NK-κB signaling and has been shown to 
The studies noted above demonstrate that CS exposure 
decreases NLRX1 expression, and NLRX1 has been reported to 
be an inhibitor of MAVS (6, 7). Thus, we next conducted studies 
to determine whether mitochondria, in particular MAVS, play 
an important effector role in CS-induced inflammation and 
remodeling. First, we compared CS-induced responses in WT 
mice with those in Mavs–/– mice. We found that inflammation 
and alveolar destruction were significantly decreased in lungs 
from CS-exposed Mavs–/– mice compared with WT controls (Fig-
ure 3, A and B, and Supplemental Figure 18). CS-induced activa-
tion of caspase 1, protease responses, IL-1β and IL-18, TUNEL 
staining, and type 1 IFN production were also diminished in the 
absence of MAVS (Figure 3C, Supplemental Figure 19, and data 
not shown). In contrast, CS-induced suppression of NLRX1 was 
not altered in the lungs of Mavs–/– mice exposed to CS for up to 6 
months (Supplemental Figure 19C). Next, to determine whether 
MAVS played a critical role in the enhancement of CS-induced 
inflammation and alveolar destruction observed in Nlrx1–/– mice, 
we exposed NLRX1 and MAVS double-mutant (Nlrx1–/– Mavs–/–) 
mice and appropriate controls to CS for 3 months. These studies 
demonstrated that the enhanced emphysema, cell death, IL-18 
production, and CXCL13 production observed in NLRX1 sin-
gle-null mice exposed to CS were decreased in similarly exposed 
double-mutant mice (Figure 3, D–F, and Supplemental Figures 
20 and 21). Overall, these studies demonstrate that MAVS plays 
Figure 3. Role of MAVS in CS-induced pulmonary inflammation and alveolar destruction. After 6 months of CS exposure, the role of MAVS was evaluated. 
(A) BAL total cell recovery and (B) mean chord length. (C) Western blot analyses of lung lysates were used to demonstrate the activation status of IL-18 and 
caspase 1. (D–F) Results of the evaluation of mean chord length, TUNEL staining of structural cells, and IL-18 levels in lung tissues from Mavs–/– Nlrx1–/–, 
Nlrx1–/–, and WT control (Mavs+/+ Nlrx1+/+) mice after a 3-month exposure to CS. Values in A, B, D, and F represent the mean ± SEM of evaluations in a mini-
mum of 5 mice (*P < 0.05; **P < 0.01). Panel C is representative of a minimum of 3 similar evaluations. A 2-way ANOVA test was used for A, B, D, and F.
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Methods
For more detailed information, see the Supplemental Methods.
Study populations. Three human cohorts from North America and 
Asia were evaluated in these studies.
Statistics. All data represent the mean ± SEM. Statistical signifi-
cance was defined at a P value of 0.05 or less. All analyses were per-
formed using SPSS software, version 22.0 (IBM Corporation).
Study approval. All human studies were approved by the Human 
Investigation Committee (HIC) of Yale University (HIC 110508577) 
and the LTRC, a nationwide resource program of the National Heart, 
Lung, and Blood Institute (NHLBI) (LTRC 11-99-0005). All in vivo 
experiments in animals were approved by the Yale Animal Care and 
Use Committee (YACUC; 2011-07586).
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regulate autophagy (6, 9, 10), bind to UQCRC2 in mitochondrial 
respiratory chain complex III, and regulate mitochondrial pro-
duction of ROS (11). This effector repertoire might have signifi-
cant implications for our studies, because defects in autophagy/
mitophagy lead to the accumulation of damaged, ROS-producing 
mitochondria, which induce inflammasome activation (12). In 
accord with this concept, a recent report demonstrated that MAVS 
also plays a role as a critical adaptor molecule in inflammasome 
activation (13). Taken together, these studies suggest that NLRX1 
inhibition of MAVS-dependent inflammasome activation plays an 
important role in the pathogenesis of COPD. Additional investi-
gation will be required to define the mechanism(s) that CS uses to 
inhibit NLRX1, the mechanism(s) that NLRX1 uses to control CS- 
and MAVS-dependent responses, and the pathway(s) that domi-
nate in the generation of COPD.
In summary, these studies demonstrate that the suppression 
of NLRX1 is a critical event in CS-induced responses. They also 
raise the possibility that the degree of NLRX1 suppression may 
be an important index of COPD severity and that polymorphisms 
or other alterations that decrease NLRX1 function can contrib-
ute to disease susceptibility. Importantly, the demonstration that 
NLRX1 supplementation abrogates CS-induced alveolar destruc-
tion also suggests that interventions that prevent the inhibition 
of NLRX1, augment the effects of NLRX1, abrogate MAVS func-
tion, or restore NLRX1 suppression may be therapeutically useful 
in this disease. Additional investigation of these possibilities in 
COPD and other CS-related diseases is warranted.
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